SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
1.310
-0.010 (-0.77%)
Nov 5, 2024, 10:51 AM EST - Market open
SCYNEXIS Employees
SCYNEXIS had 29 employees as of December 31, 2023. The number of employees decreased by 7 or -19.44% compared to the previous year.
Employees
29
Change (1Y)
-7
Growth (1Y)
-19.44%
Revenue / Employee
$333,310
Profits / Employee
-$1,220,345
Market Cap
49.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Fortress Biotech | 186 |
Aadi Bioscience | 89 |
Affimed | 76 |
Lucid Diagnostics | 70 |
Kezar Life Sciences | 58 |
OncoCyte | 46 |
LAVA Therapeutics | 37 |
Elicio Therapeutics | 32 |
SCYX News
- 26 days ago - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 4 weeks ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - GlobeNewsWire
- 2 months ago - SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports - GlobeNewsWire
- 6 months ago - SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) - GlobeNewsWire
- 7 months ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - GlobeNewsWire